Angiogenic growth factors

doi:10.1016/0955-2235(90)90010-H

Progress in Growth Factor Research

Volume 2, Issue 1, 1990, Pages 71-79

Progress in Growth F...

https://doi.org/10.1016/0955-2235(90)90010-H Get rights and content

Abstract

Angiogenesis, the formation of new blood vessels, plays a central role in a variety of physiological and pathological processes such as embryonic development, wound healing and tumor growth. It is a complex, multi-step process that involves the migration and proliferation of capillary endothelial cells. Several factors that stimulate the proliferation of endothelial cells in vitro have been shown to induce angiogenesis in vivo. Among these angiogenic growth factors are wide-spectrum multifunctional mitogens (e.g. the fibroblast growth factors) and the recently identified factors with distinct specificity for vascular endothelial cells (e.g. the platelet-derived endothelial cell growth factor). Another group of factors apparently induce angiogenesis indirectly (e.g. transforming growth factor-β) by stimulating target cells to release angiogenic factors or by other mechanisms. The differential expression, release and activation of these factors might regulate angiogenesis under various physiological and pathological conditions.

References (65)

W Risau et al.
Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis
Dev Biol.
(1988)
D Gospodarowicz et al.
Fibroblast growth factor
Mol Cell Endocrinol.
(1986)
KA Thomas et al.
Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity
TIBS
(1986)
R Lobb et al.
Purification and characterization of heparin-binding endothelial cell growth factors
J Biol Chem.
(1986)
F Mascarelli et al.
Characterization of acidic and basic fibroblast growth factors in brain, retina and vitreous chick embryo
Biochem Biophys Res Commun.
(1987)
Y-A Barde
Trophic factors and neuronal survival
Neuron
(1989)
HR Woodland
Mesoderm formation in Xenopus
Cell
(1989)
N Ferrara et al.
Pituitary follicular cells secrete a novel heparin-binding growth-factor specific for vascular endothelial-cells
Biochem Biophys Res Commun.
(1989)
M Frater-Schröder et al.
Transforming growth factor-beta inhibits endothelial cell proliferation
Biochem Biophys Res Commun.
(1986)
DM Wiseman et al.
Transforming growth factor-beta (TGF-β) is chemotactic for human monocytes and induces their expression of angiogenic activity
Biochem Biophys Res Commun.
(1988)

RL Williams et al.

Endothelioma cells expressing the polyoma middle-T oncogene induce hemangiomas by host-cell recruitment

Cell

(1989)

C Dickson et al.

The structure and function of the int-2 oncogene

Prog Growth Factor Res.

(1989)

PG Milner et al.

A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: Purification and N-terminal amino acid sequence

Biochem Biophys Res Commun.

(1989)

W Risau et al.

Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies

Development

(1989)

L Pardanaud et al.

Relationship between vasculogenesis, angiogenesis and hematopoiesis during avian ontogeny

Development

(1989)

DJ Coffin et al.

Embryonic vascular development: immunohistochemical identification of the origin and subsequent morphogenesis of the major vessel primordia in quail embryos

Development

(1988)

PA D'Amore et al.

Mechanisms of angiogenesis

Annu Rev Physiol.

(1987)

HM Evans

On the development of the aortae, cardinal and umbilical veins, and the other blood vessels of vertebrate embryos from capillaries

Anat Rec.

(1909)

FR Sabin

Studies of the origin of the blood vessels and of red blood corpuscles as seen in the living blastoderm of chick during the second day of incubation

Carnergie Contrib Embryol.

(1920)

RL Engerman et al.

Cell turnover of capillaries

Lab Invest.

(1967)

J Folkman et al.

Angiogenic factors

Science

(1987)

D Ausprunk et al.

Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis

Microvasc Res.

(1977)

J Folkman

How is blood vessel growth regulated in normal and neoplastic tissue?

G.H.A. Clowes Memorial Award Lecture. Cancer Res.

(1986)

Y Shing et al.

Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor

Science

(1984)

Y Shing et al.

Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor

J Cell Biochem.

(1985)

M Klagsbrun et al.

Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor

F Esch et al.

Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF

G Gimenez-Gallego et al.

Brain-derived acidic fibroblast growth factor: complete amino acid sequence and homologies

Science

(1985)

WH Burgess et al.

The heparin-binding (fibroblast) growth factor family of proteins

Annu Rev Biochem.

(1989)

W Risau

Developing brain produces an angiogenesis factor

W Risau et al.

Production of a heparin-binding angiogenesis factor by the embryonic kidney

J Cell Biol.

(1986)

D Moscatelli et al.

Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration

Cited by (149)

Agrimonia eupatoria L. and wound healing
2023, Journal of Herbal Medicine
The beneficial effect of common agrimony (Agrimonia eupatoria L.) on chronic wound healing has been repeatedly observed. According to the literature, this herb has been used, either in monotherapy or in combination with other herbs, in traditional medicine since ancient times.
The large body of our clinical experience with wound healing with agrimony has prompted us to review the current literature on the efficacy and mechanisms of action of its individual components.
Relevant studies were identified by PubMed, Google Scholar and ScienceDirect. Reference lists of retrieved articles were also reviewed. The major search engines used relevant information from articles and books, checked references and contacted study authors to identify additional studies.
Scientific evidence of agrimony’s efficacy and mechanisms of action on wound healing is still lacking. We realised that most studies, while focusing on the herb’s antimicrobial and antioxidant properties, failed to offer comprehensive reviews of agrimony’s exact actions at the molecular level. In our review, we sought to analyse the results of individual experimental studies and relate them to the individual phases of healing.
The value of the topical application of A eupatoria L. infusions is verified by the long-standing experience of traditional medicine. Partial results of individual studies document evidence-based justification of the plant’s use in clinical practice; this, however, still warrants further specific clinical testing and verification of its efficacy using the criteria of evidence-based medicine.
Strategies targeting tumor immune and stromal microenvironment and their clinical relevance
2022, Advanced Drug Delivery Reviews
Citation Excerpt :
Nevertheless, a variety of tumor VEC-targeting ligands/materials have been developed for nano delivery systems to reduce off-target effect toward normal VECs [184], including peptides (e.g., Arginine-Glycine-Aspartic acid (RGD) and Asparagine-Glycine-Arginine (NGR) motifs), antibodies (e.g., anti-VEGFR), carbohydrate moieties (e.g., Sialyl LewisX), cationic lipids, and synthetic polymers with high affinity for VEGF [185]. Tumor angiogenesis is driven by endothelial signaling cascades initiated by interactions between pro-angiogenic growth factors(e.g., VEGF [186], PDGF [187], fibroblast growth factor (FGF) [188]) and receptor tyrosine kinases (RTKs) (e.g., VEGFR, PDGF receptor, FGF receptor) (Table 8). AIs targeting this signaling including VEGF capturers such as bevacizumab and ziv-aflibercept (recombinant fusion protein binding diffusible VEGF) and RTK antagonists such as ramucirumab and lenvatinib, have been approved for multiple cancer types including CRC, NSCLC, RCC, cervical cancer, glioblastoma (www.accessdata.fda.gov).
The critical role of tumor microenvironment (TME) in tumor initiation and development has been well-recognized after more than a century of studies. Numerous therapeutic approaches targeting TME are rapidly developed including those leveraging nanotechnology, which have been further accelerated since the emergence of immune checkpoint blockade therapies in the past decade. While there are many reviews focusing on TME remodeling therapies via drug delivery and engineering strategies in animal models, state-of-the-art evaluation of clinical development states of TME-targeted therapeutics is rarely found. Here, we illustrate opportunities for integrating nano-delivery system for the development of TME-specific therapeutic regimen, followed by a comprehensive summary of the most up to date approved or clinically evaluated therapeutics targeting cellular and extracellular components within tumor immune and stromal microenvironment, including small molecule and monoclonal antibody drugs as well as nanomedicines. In the end, we also discuss challenges and possible solutions for clinical translation of TME-targeted nanomedicines.
Development of a gel-in-oil emulsion as a transdermal drug delivery system for successful delivery of growth factors
2021, Journal of Bioscience and Bioengineering
Citation Excerpt :
Our results showed the highest angiogenic effect with the Hep-bFGF-G/O condition after transdermal application in comparison to that with Hep-G/O and G/O. Therefore, it was confirmed that bFGF included in the G/O emulsion maintained its activity and was delivered and released into the skin effectively. When a transdermal administration of bFGF-immobilized G/O emulsion was performed, an increase in the network of blood vessels promoted by bFGF, a potent angiogenic factor, was suggested (9,36). Therefore, it was confirmed that bFGF, which is included in the G/O emulsion maintained its activity, was delivered, and released into the skin.
Growth factors (GFs) are indispensable in regenerative medicine because of their high effectiveness. However, as GFs degenerate easily, the development of a suitable carrier with improved stability for GFs is necessary. In this study, we developed a gel-in-oil (G/O) emulsion technology for the transdermal delivery of growth factors. Nanogel particles prepared with heparin-immobilized gelatin that can bind growth factors were dispersed in isopropyl myristate. The particle size of the G/O emulsion could be controlled by changing the surfactant concentration, volume ratio of the water phase to the oil phase, and gelatin concentration. In vitro skin penetration studies showed better penetration through the stratum corneum of fluorescent proteins containing G/O emulsions than of the aqueous solution of GF. Similarly, an in vivo study showed an angiogenesis-inducing effect after transdermal application of GF-immobilized G/O emulsion. Angiogenesis in mice was confirmed owing to both an increased blood vessel network and higher hemoglobin content in the blood. Therefore, the G/O emulsion could be a promising carrier for GFs with better stability and can effectively deliver GFs at the target site.
Phenotypic characteristics of human bone marrow-derived endothelial progenitor cells in vitro support cell effectiveness for repair of the blood-spinal cord barrier in ALS
2019, Brain Research
Citation Excerpt :
However, the mechanisms of transplanted cell actions are still unclear. Various angiogenic growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor (TGF)-β, angiogenin, endoglin, platelet-derived growth factor (PDGF) and others play essential roles in EC proliferation, maturation, and integration for promoting angiogenesis, vasculogenesis, and/or revascularization (reviewed in (Crivellato, 2011; Díaz-Flores et al., 1994; Draoui et al., 2017; Rafii and Lyden, 2003; Ribatti and Crivellato, 2012; Risau, 1990; Urbich and Dimmeler, 2004)). Studies demonstrated that several factors (i.e. VEGF (Hoeben et al., 2004; Tammela et al., 2005) and FGF (Esser et al., 2015)), which stimulate the proliferation of ECs in vitro, also induce angiogenesis in vivo.
Amyotrophic lateral sclerosis (ALS) was recently recognized as a neurovascular disease. Accumulating evidence demonstrated blood-spinal-cord barrier (BSCB) impairment mainly via endothelial cell (EC) degeneration in ALS patients and animal models. BSCB repair may be a therapeutic approach for ALS. We showed benefits of human bone marrow endothelial progenitor cell (hBMEPC) transplantation into symptomatic ALS mice on barrier restoration; however, cellular mechanisms remain unclear. The study aimed to characterize hBMEPCs in vitro under normogenic conditions. hBMEPCs were cultured at different time points. Enzyme-linked immunosorbent assay (ELISA) was used to detect concentrations of angiogenic factors (VEGF-A, angiogenin-1, and endoglin) and angiogenic inhibitor endostatin in conditioned media. Double immunocytochemical staining for CD105, ZO-1, and occludin with F-actin was performed. Results showed predominantly gradual significant post-culture increases of VEGF-A and angiogenin-1 levels. Cultured cells displayed distinct rounded or elongated cellular morphologies and positively immunoexpressed for CD105, indicating EC phenotype. Cytoskeletal F-actin filaments were re-arranged according to cell morphologies. Immunopositive expressions for ZO-1 were detected near inner cell membrane and for occludin on cell membrane surface of adjacent hBMEPCs. Together, secretion of angiogenic factors by cultured cells provides evidence for a potential mechanism underlying endogenous EC repair in ALS through hBMEPC transplantation, leading to restored barrier integrity. Also, ZO-1 and occludin immunoexpressions, confirming hBMEPC interactions in vitro, may reflect post-transplant cell actions in vivo.
Heparin-Based Coacervate of FGF2 Improves Dermal Regeneration by Asserting a Synergistic Role with Cell Proliferation and Endogenous Facilitated VEGF for Cutaneous Wound Healing
2016, Biomacromolecules
Effective wound healing requires complicated, coordinated interactions and responses at protein, cellular, and tissue levels involving growth factor expression, cell proliferation, wound closure, granulation tissue formation, and vascularization. In this study, we develop a heparin-based coacervate consisting of poly(ethylene argininylaspartate digylceride) (PEAD) as a storage matrix, heparin as a bridge, and fibroblast growth factor-2 (FGF2) as a cargo (namely heparin-FGF2@PEAD) for wound healing. First, in vitro characterization demonstrates the loading efficiency and control release of FGF2 from the heparin-FGF2@PEAD coacervate. The following in vivo studies examine the wound healing efficiency of the heparin-FGF2@PEAD coacervate upon delivering FGF2 to full-thickness excisional skin wounds in vivo, in comparison with the other three control groups with saline, heparin@PEAD as vehicle, and free FGF2. Collective in vivo data show that controlled release of FGF2 to the wounds by the coacervate significantly accelerates the wound healing by promoting cell proliferation, stimulating the secretion of vascular endothelial growth factor (VEGF) for re-epithelization, collagen deposition, and granulation tissue formation, and enhancing the expression of platelet endothelial cell adhesion molecule (CD31) and alpha-smooth muscle actin (α-SMA) for blood vessel maturation. In parallel, no obvious wound healing effect is found for the control, vehicle, and free FGF2 groups, indicating the important role of the coavervate in the wound healing process. This work designs a suitable delivery system that can protect and release FGF2 in a sustained and controlled manner, which provides a promising therapeutic potential for topical treatment of wounds.
Production of functional active human growth factors in insects used as living biofactories
2014, Journal of Biotechnology
Growth factors (GFs) are naturally signalling proteins, which bind to specific receptors on the cell surface. Numerous families of GFs have already been identified and remarkable progresses have been made in understanding the pathways that these proteins use to activate/regulate the complex signalling network involved in cell proliferation or wound healing processes. The bottleneck for a wider clinical and commercial application of these factors relay on their scalable cost-efficient production as bioactive molecules. The present work describes the capacity of Trichoplusia ni insect larvae used as living bioreactors in combination with the baculovirus vector expression system to produce three fully functional human GFs, the human epidermal growth factor (huEGF), the human fibroblast growth factor 2 (huFGF2) and the human keratinocyte growth factor 1 (huKGF1). The expression levels obtained per g of insect biomass were of 9.1, 2.6 and 3 mg for huEGF, huFGF2 and huKGF1, respectively. Attempts to increase the productivity of the insect/baculovirus system we have used different modifications to optimize their production. Additionally, recombinant proteins were expressed fused to different tags to facilitate their purification. Interestingly, the expression of huKGF1 was significantly improved when expressed fused to the fragment crystallizable region (Fc) of the human antibody IgG. The insect-derived recombinant GFs were finally characterized in terms of biological activity in keratinocytes and fibroblasts. The present work opens the possibility of a cost-efficient and scalable production of these highly valuable molecules in a system that favours its wide use in therapeutic or cosmetic applications.

View all citing articles on Scopus

View full text

Angiogenic growth factors

Abstract

Dev Biol.

Mol Cell Endocrinol.

TIBS

J Biol Chem.

Biochem Biophys Res Commun.

Neuron

Cell

Biochem Biophys Res Commun.

Biochem Biophys Res Commun.

Biochem Biophys Res Commun.

Cell

Prog Growth Factor Res.

Biochem Biophys Res Commun.

Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies

Development

Relationship between vasculogenesis, angiogenesis and hematopoiesis during avian ontogeny

Development

Embryonic vascular development: immunohistochemical identification of the origin and subsequent morphogenesis of the major vessel primordia in quail embryos

Development

Mechanisms of angiogenesis

Annu Rev Physiol.

On the development of the aortae, cardinal and umbilical veins, and the other blood vessels of vertebrate embryos from capillaries

Anat Rec.

Studies of the origin of the blood vessels and of red blood corpuscles as seen in the living blastoderm of chick during the second day of incubation

Carnergie Contrib Embryol.

Cell turnover of capillaries

Lab Invest.

Angiogenic factors

Science

Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis

Microvasc Res.

How is blood vessel growth regulated in normal and neoplastic tissue?

G.H.A. Clowes Memorial Award Lecture. Cancer Res.

Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor

Science

Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor

J Cell Biochem.

Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor

Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF

Brain-derived acidic fibroblast growth factor: complete amino acid sequence and homologies

Science

The heparin-binding (fibroblast) growth factor family of proteins

Annu Rev Biochem.

Developing brain produces an angiogenesis factor

Production of a heparin-binding angiogenesis factor by the embryonic kidney

J Cell Biol.

Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration